Summary & Overview
HCPCS G9821: No Documentation of Chlamydia Screening Test with Proper Follow-Up
HCPCS Level II code G9821 denotes lack of documentation for a chlamydia screening test with appropriate follow-up. As a clinical quality measure marker, this code signals a gap in preventive sexual health services and medical record completeness. On a national scale, documenting screening and follow-up for chlamydia is important for patient safety, public health surveillance, and quality reporting.
Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find information on how G9821 is used as an indicator of documentation gaps, the typical clinical and service settings where the issue arises, and the implications for quality measurement and reporting across major payers. The publication summarizes benchmark considerations, common billing contexts, and the clinical context for chlamydia screening and follow-up procedures.
The analysis provides: an explanation of the code and its clinical relevance; benchmarks and payer perspectives where available; and context on typical service lines and sites. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9821 indicates no documentation of a chlamydia screening test with proper follow-up. The code captures instances where a chlamydia screening was indicated but either the test was not documented in the medical record or appropriate follow-up actions were not recorded.
-
Service type: Preventive screening / screening quality measure
-
Typical site of service: Outpatient clinic or ambulatory care setting, including primary care and sexual health clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 22-year-old sexually active female presents to a community health clinic for a routine annual exam. The clinician intends to perform a chlamydia screening test as part of sexually transmitted infection (STI) prevention and reproductive health care. A nucleic acid amplification test (NAAT) is ordered on a urine specimen or vaginal swab. Results are expected within 48–72 hours. Proper follow-up includes documenting test results in the medical record, delivering positive results promptly, notifying and treating exposed partners per local public health protocols, and documenting counseling and treatment or retesting plans. The typical clinical workflow: history and risk assessment → specimen collection for NAAT → lab processing → clinician documents results and follow-up plan in the chart or contacts the patient for positive result management. Billing for the encounter may reference quality reporting or performance measures when a screening was intended; the billing code G9821 is used when there is no documentation of a chlamydia screening test with proper follow-up.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when services are substantially greater than typically required; rare for simple screening encounters. |